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bstract
We summarize findings of SARS-CoV infections in several animal models each of which support viral replication in lungs accompanied by 
istopathological changes and/or clinical signs of illness to varying degrees. New findings are reported on SARS-CoV replication and associated 
athology in two additional strains (C57BL/6 and 129S6) of aged mice. We also provide new comparative data on viral replication and associated 
athology following infection of golden Syrian hamsters with various SARS-CoV strains and report the levels of neutralizing antibody titers 
ollowing these infections and the cross-protective efficacy of infection with these strains in protecting against heterologous challenge. Finally, 
e summarize findings of a variety of vaccine approaches and discuss the available in vitro and in vivo data addressing the potential for disease 
nhancement following re-infection in animals previously vaccinated against or infected with SARS-CoV.
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. Introduction
In studies of pathogenesis, prophylaxis, and treatment, ani-
al models that mimic human disease and protection from
isease are invaluable. Since the outbreak of severe acute respi-
atory syndrome (SARS) in late 2002 and identification of the
tiological agent as a novel coronavirus (SARS-CoV) in 2003,
everal animal models have been identified for use in such eval-
ations. Although each model reviewed in this article has some
tility in the study of SARS disease and prevention, the kinetics
f viral replication and resolution of disease are much more rapid
n animal models compared to human infections, and no model
ully reflects the spectrum of clinical illness (morbidity and mor-
ality), associated pathology, and viral replication observed in
uman cases of SARS. Of the animal models that have been
mployed for evaluating SARS-CoV replication and disease,
hose models that have been most fully characterized and which
ffer the best potential for evaluation of prevention and ther-
peutic strategies are discussed here and include inbred mice,
∗ Corresponding author. Tel.: +1 301 451 3839; fax: +1 301 496 8312.
E-mail address: ksubbarao@niaid.nih.gov (K. Subbarao).
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oi:10.1016/j.virusres.2007.03.025on-human primates; Vaccines; FIPV; Enhanced disease; Urbani; HKU-39849; 
amsters, ferrets and non-human primates. We also reference
ther, less well-characterized animal models.
A number of approaches for the development of SARS vac-
ines have been explored, including inactivated whole-virus,
rotein subunit, live virus-vectored, DNA-vectored, and combi-
ation vaccines. We review the data available on the evaluation
f these candidate vaccines.
Lastly, we address the potential for enhanced disease follow-
ng exposure to SARS-CoV in previously vaccinated animals.
he potential for this phenomenon is given special considera-
ion because immunization of kittens with a type-1 coronavirus
accine against feline infectious peritonitis virus (FIPV) led to
xacerbated disease following challenge with FIPV. This has
ed to concern and speculation about the potential for disease
nhancement following use of SARS vaccines.
. Animal models.1. Inbred mice
Several inbred mouse species (BALB/c, C57BL/6 (B6),
29S) have been shown to support SARS-CoV replication and
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Fig. 1. Replication of SARS-CoV in lungs of aged B6 and BALB/c mice. B6 and
BALB/c mice (N = 15 per strain, aged 12–14 months) were intranasally infected
with SARS-CoV (105 TCID50/mouse) at day 0. Five mice per strain were sac-
rificed at days 2, 5 and 6 post-infection. Bars (hatched = B6; open = BALB/c)
indicate the mean titer of virus detected in 10% (w/v) lung homogenates by
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ao demonstrate pneumonitis (129S) and clinical signs of SARS
isease (aged BALB/c) (Glass et al., 2004; Hogan et al., 2004;
oberts et al., 2005a; Subbarao et al., 2004). The inbred mouse
odel has several advantages including small size, cost, avail-
bility in large enough numbers for statistical evaluation, and the
bility to be manipulated at a genetic level (i.e. to develop gene
nock-outs and knock-ins). In addition, immunological reagents
re available for studying elements of pathogenesis in many
nbred mouse strains.
Following intranasal inoculation under light anesthesia,
ARS-CoV replicates in the epithelium of nasal turbinates and
ungs of mice as early as 1 day post-infection (p.i.). The peak titer
n lungs occurs at days 2–3 p.i., and virus is cleared in most mice
y days 5–7 p.i. In young mice, SARS-CoV replication has not
een associated with overt signs of clinical illness or pronounced
athology. However, 129S6 mice seem to be slightly more sus-
eptible to disease associated with SARS-CoV infection than
re BALB/c or B6 mice, as evidenced by an approximate 8%
oss of body weight, with a nadir at days 5–7 p.i., and by the pres-
nce of mild interstitial pneumonitis at day 2 p.i. (Hogan et al.,
004; authors’ unpublished data). Interstitial pneumonitis fol-
owing SARS-CoV infection has not been previously reported
n BALB/c mice when evaluated at days 2, 4 and 9 p.i. (Subbarao
t al., 2004). However, slightly elevated levels of the proinflam-
atory cytokine TNF-alpha were observed in young BALB/c
ice at day 3 p.i. (authors’ unpublished data), and upon recent
valuation, young BALB/c mice displayed moderate interstitial
neumonitis on day 3 p.i., comparable to that seen in B6 and
ag1−/− mice (Glass et al., 2004; Roberts et al., 2007). This
neumonitis is quickly resolved and is not observed on day 4 p.i.
his transient inflammation coincides with viral clearance since
ittle viral antigen is observed at or after day 3 p.i., and virus titers
n lungs also steadily decline from day 3 p.i. onwards (Subbarao
t al., 2004).
Aged BALB/c mice develop more severe disease than young
ALB/c mice in a pattern of age-related severity that mimics
bservations in the SARS outbreak in humans, where age was a
redictor of severe disease and mortality (Roberts et al., 2005a).
n addition to serving as a model of age-related susceptibility
o disease, aged BALB/c mice consistently demonstrate several
eatures of an ideal animal model for SARS-CoV studies. In
ddition to supporting viral replication in respiratory tissues, the
ged BALB/c mouse (BALB/cAnNHsd, Harlan) demonstrates
linical signs of illness including weight loss, dehydration, and
uffled fur, and several histopathological findings, i.e. diffuse
lveolar damage including edema, hyaline membrane formation,
nd pneumonitis, that correlate with those reported in autopsies
f SARS patients (Roberts et al., 2005a).
We also examined the susceptibility of aged C57BL/6J (The
ackson Laboratory, B6) and 129S6/SvEvTac (Taconic, 129S6)
ice to SARS-CoV infection. Following intranasal inoculation
ith 105 TCID50 of SARS-CoV (Urbani), both B6 and 129S6
ged mice (12–14 months old) had weight loss (∼7% at the
adir) from day 3 through day 5 p.i. that was comparable to that
bserved in aged BALB/c mice (Roberts et al., 2005a). The level
nd kinetics of viral replication in lungs of aged B6 and BALB/c
ice following inoculation were also similar. At days 5 and
h
m
2
v0% tissue culture infectious dose (TCID50) assays on Vero cell monolay-
rs. Error bars indicate standard error. Dashed line indicates limit of detection,
01.5 TCID50/g lung.
p.i., SARS-CoV-infected B6 mice had 10–70-fold lower titers
f virus than BALB/c mice (Fig. 1). In contrast, aged 129S6 mice
id not support prolonged replication of SARS-CoV as virus
as cleared from lungs by day 5 p.i. (data not shown). Neverthe-
ess, early histopathological features in the lungs of aged B6 and
29S6 mice were similar to those seen in aged BALB/c mice fol-
owing SARS-CoV infection. Changes observed in the lungs at
ay 3 p.i included perivascular and peribronchiolar mononuclear
nflammatory infiltrates, intraluminal necrotic debris in bronchi-
les comprised of dead respiratory epithelium and inflammatory
ells, and small foci of interstitial pneumonitis (Fig. 2A, C, and
). Viral antigens were detected by immunohistochemical (IHC)
taining in the respiratory epithelial cells of bronchioles and
n alveolar pneumocytes of all mouse strains at day 3 p.i., but
ppeared most abundant in the bronchioles of 129S6 mice at this
ime point (Fig. 2B, C and F). Varying amounts of mononuclear
nflammatory infiltrates persisted around bronchioles and small
ulmonary vessels through day 9 p.i.; however, no viral antigens
ere detected by IHC at this time point. As previously reported,
he aged BALB/c mouse has features that would make it an excel-
ent model for evaluation of pathogenesis and vaccine efficacy
tudies. Based on weight loss and histopathological analyses,
e believe that aged B6 and 129S6 mice may provide addi-
ional models for the study of age-dependent susceptibility to
ARS-CoV. However, the drawback to widespread utility of the
ged mouse model is the difficulty in procuring large numbers
f mice that are over 12 months of age.
Although a few strains of mice with targeted deletions
f genes have been evaluated following SARS-CoV infec-
ion including Rag1−/−, CD1−/−, and Beige mice (Glass et
l., 2004), the only strain with a notable clinical course or
istopathological outcome different from wild-type strains of
ice are STAT1−/− mice in the 129S background (Hogan et al.,
004; authors’ unpublished data). These mice support prolonged
iral replication in the lungs with accompanying pathology,
Fig. 2. Histopathologic features of infection with SARS-CoV in the lungs of aged 129S6, B6 and BALB/c mice at 3 days post-infection. (A) Florid perivascular and
peribronchiolar inflammatory cell infiltrates comprised predominantly of mononuclear cells (strain 129S6, original magnification 25×). (B) Abundant SARS-CoV
antigens (red) in the cytoplasm of bronchiolar epithelial cells (strain 129S6, original magnification 50×). (C) Necrotic respiratory epithelium and inflammatory cells
in the lumen of a small pulmonary bronchiole (strain BL6, original magnification 50×). (D) Immunohistochemical staining of the same section in C, showing scattered
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ntigen in alveolar pneumocytes adjacent to a bronchiole (strain BALB/c, ori
hosphatase with naphthol fast-red substrate and hematoxylin counterstain (B,
iremia, and dissemination of virus to the liver and spleen.
hese mice are suitable for pathogenesis studies and evalua-
ion of antiviral agents. Other wild-type strains of inbred mice
re suitable for studies of immunopathology, immunogenicity
nd efficacy of vaccine candidates.
.2. Golden Syrian hamsters
The golden Syrian hamster (strain LVG, Charles River Lab-
ratories; http://www.criver.com/research models and services/
esearch models/LVG Hamsters.html) is an excellent model for
ARS-CoV infection because viral replication is accompanied
y pathological changes in the lungs including pneumonitis
nd consolidation (Roberts et al., 2005b). Following intranasal
noculation with 103 TCID50 SARS-CoV, hamsters support
iral replication in the nasal turbinates and lungs. Peak viral
eplication in the lungs occurs at day 3 p.i. and is cleared by
h
a
a
ty cell infiltrate (strain BALB/c, original magnification 50×). (F) SARS-CoV
magnification 50×). Hematoxylin and eosin stain (A, C, E); immunoalkaline
ay 7 p.i. Virus titers in nasal turbinates are about 10–100-fold
ower than in lungs, but are detectable through day 14 p.i.
iremia is detected 2–3 days p.i.; and virus can be recovered
rom the spleen and liver. Histopathological changes in the
ungs accompany SARS-CoV infection of hamsters. By day
p.i., focal areas of interstitial inflammation and consolidation
re visible. At day 5 p.i., inflammation is more pronounced
nd consolidation is more widespread. Consolidation continues
hrough day 7 p.i. and involves 30–40% of the surface area of
he lung. By day 21 p.i., pathological changes in the lung have
esolved (Roberts et al., 2005b).
Although histopathological signs of disease are pronounced,
linical symptoms of disease have been difficult to identify in
amsters. However, use of exercise wheels to evaluate overnight
ctivity demonstrates that hamsters infected with SARS-CoV
re less active from day 2 through day 7 p.i. than they were prior
o infection or compared to uninfected or mock-infected animals
Table 1
Reduced activity in SARS-CoV-infected hamsters
Inoculation group Average no. of revolutions per hour ± S.E.
Prior to infection Days 2–4 p.i. Days 9–10 p.i.
SARS-CoV Urbani 865 ± 25 61 ± 23 770 ± 5Mock-infected 946 ± 21 726 ± 46
Golden Syrian hamsters, 5–10 weeks old, were allowed to run overnight in an
ABSL3 animal containment facility under a biosafety cabinet on a Nalgene
activity wheel for rodents equipped with a magnetic switch with LCD counter
that counts whole revolutions (Fisher Scientific). Two to five nights prior to
inoculation and one to ten nights following inoculation, hamsters were allowed
to run and the number of revolutions was recorded and reported as an average of
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eevolutions per hour; average run time 14 h/night. Each activity wheel was in a
eparate cage; one hamster per cage; water and food were available ad libitum.
amsters were rested on alternate nights.
Table 1). This is the first objective evidence of clinical illness
n hamsters.
.3. Evaluation of various strains of SARS-CoV in hamsters
Several strains of SARS-CoV have been evaluated in the
amster model, including Urbani (GenBank no. AY27874),
KU-39849 (HK-39; GenBank no. AY278491), Frankfurt 1Frk-1; GenBank no. AY291315) and a recombinant SARS-
oV infectious clone (ic) expressing the spike protein of
D03T0013 (GenBank no. AY525636) (icGD03; Deming et al.,
006). Primary intranasal infection with 103 TCID50/hamster
r
(
g
ig. 3. Primary replication and replication after challenge of SARS-CoV in hamster
ith one of four SARS-CoV strains (A) HK-39 (N = 16), (B) Urbani (N = 16), (C) F
or evaluating viral replication following primary (1◦) infection, four hamsters pe
or evaluation of protection from secondary (2◦) infection, the remaining hamsters
eterologous strain of SARS-CoV (N = 4 per group; or N = 3/group for icGD03; 103 T
etected in 10% (w/v) lung homogenates by TCID50 assay on Vero cells (1◦ = day 2
rror. Dashed line indicates limit of detection, 101.5 TCID50/g lung.ith SARS-CoV (Urbani, HK-39 or Frk-1) results in virus titers
f >107 TCID50/g of lung by day 2 p.i. (Fig. 3A–C), whereas pri-
ary infection with icGD03 results in significantly lower titers
104 TCID50/g on day 2 p.i.) (Fig. 3D). Our findings suggest that
ompared with the Urbani strain, icGD03 is slightly attenuated
n the hamster model with a 1000-fold reduction in peak virus
iters in the lungs following infection, and that SARS-CoV Frk-
may be slightly more virulent than other strains. Although
ose-dependent mortality was not observed, 3 of 20 hamsters
ied following infection with SARS-CoV Frk-1, and peak virus
iters in lungs are higher than peak virus titers following infection
ith Urbani or HK-39. However, the difference in peak virus titer
id not achieve statistical significance (Fig. 3A–C). Histopatho-
ogical findings in lungs following infection with SARS-CoV
HK-39 or Frk-1) are indistinguishable from those reported fol-
owing infection with SARS-CoV (Urbani) (Fig. 4). The spike
roteins of the SARS-CoV Urbani and HK-39 isolates are identi-
al in amino acid sequence, and the Frk-1 spike protein sequence
iffers from these by only one amino acid in the S2 domain
L1148F). Antibodies detected in hamster sera following pri-
ary SARS-CoV infections cross-neutralize the various virus
trains and homologous viruses to comparable degrees (Urbani,
rk-1 and HK-39: ∼1:500 to 1:1000), and hamsters infected
ith each of these strains of SARS-CoV are protected frome-infection with the homologous virus or heterologous viruses
Fig. 3A–D).
Although hamsters are not an inbred species, the level of
enetic variability among golden Syrian hamsters is limited
lungs. Golden Syrian hamsters (50–55 days old) were intranasally inoculated
rk-1 (N = 16), and (D) icGD03 (N = 12) of SARS-CoV (103 TCID50/hamster).
r strain (three hamsters for icGD03) were sacrificed at day 2 post-infection.
were challenged 28 days after 1◦ infection with the indicated homologous or
CID50/hamster) and sacrificed 2 days later. Bars indicate the mean titer of virus
after initial infection; 2◦ = day 2 after challenge). Error bars indicate standard
Fig. 4. Pathology in lungs of golden Syrian hamsters following SARS-CoV infection. Lungs from SARS-CoV-infected (Urbani, A and B; Frankfurt-1, C and D;
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MKU-39849, E and D) hamsters at day 5 p.i. show confluent pneumonic conso
ssays, antigen in red; B, D, and F) in consolidated areas (asterisk) and bronchia
ecause they have been a closed, outbred colony since 1951.
urthermore, since hamsters demonstrate high levels of viral
eplication, pronounced and widespread histopathological find-
ngs in the lungs, and some clinical evidence of infection
Table 1), they are suitable for vaccine efficacy, immunopro-
hylaxis and treatment studies. Although the availability of
mmunological reagents for the hamster are limited, the use of
eal-time RT-PCR to study cytokine and chemokine responses
ollowing infection may reveal mechanisms of pathogenesis in
his model and will lead to a better understanding of the patho-
enesis of SARS in humans.
.4. FerretsFerrets (Mustela furo) support SARS-CoV replication and
evelop multifocal pulmonary lesions involving 5–10% of the
urface area of the lung (ter Meulen et al., 2004). Ferrets
nfected with 103 or 104 TCID50 sustain virus replication at
t
S
t
(n (hematoxylin-and-eosin stain, A, C, and E), and SARS-CoV antigens (IHC
elium (arrows). Original magnifications: 25× (A, C and E); 50× (B, D and F).
06 TCID50/mL at day 4 p.i. (Martina et al., 2003; ter Meulen
t al., 2004) Two groups of investigators have utilized the ferret
odel with somewhat different findings (Martina et al., 2003;
er Meulen et al., 2004; Weingartl et al., 2004b), suggesting that
his model needs further characterization for vaccine efficacy
nd immunoprophylaxis studies. Clinical symptoms following
ARS-CoV infection were reported in one study (Martina et al.,
003) but not in two others (ter Meulen et al., 2004; Weingartl et
l., 2004b). Additional studies would help define the biological
ariability of this outbred species and the potential contribution
f co-pathogens to the variability observed between the differ-
nt studies. Finally although the ferret model has been used
uccessfully for immunotherapy and prophylaxis studies (ter
eulen et al., 2004), further evaluation is needed to understand
he poor efficacy and immunogenicity seen in MVA-vectored,
ARS-vaccinated ferrets (Weingartl et al., 2004b) compared to
hat observed in other animals immunized with a similar vaccine
Bisht et al., 2004; Chen et al., 2005).
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h.5. Non-human primates (NHP)
NHPs support viral replication and pneumonitis with variable
linical symptoms and pathology, depending upon the species.
arious strains of SARS-CoV, including Urbani, PUMC-01
nd HKU-39849, have been evaluated in rhesus macaques
McAuliffe et al., 2004; Qin et al., 2005; Rowe et al., 2004),
ynomolgus macaques (Fouchier et al., 2003; Kuiken et al.,
003; Lawler et al., 2006; McAuliffe et al., 2004; Qin et al.,
006; Rowe et al., 2004), common marmosets (Greenough et
l., 2005b), African green monkeys (McAuliffe et al., 2004),
quirrel monkeys and mustached tamarins. Squirrel monkeys
nd mustached tamarins were not susceptible to SARS-CoV
rbani infection (authors’ unpublished data). Virus was not
etected in the respiratory tract following inoculation and mon-
eys did not develop antibodies to SARS-CoV. All other NHP
pecies studied were susceptible to infection to variable degrees.
f these susceptible species, no single model is preferred to
ny other. Each support viral replication in lungs (Table 2)
nd viral shedding in respiratory secretions and most develop
ome histopathological changes consistent with human infec-
ions including infection of type I and type II pneumocytes and
iffuse alveolar damage. Few vaccine candidates have been eval-
ated in NHPs. The vaccines that were evaluated in NHPs were
fficacious in reducing titers of wild-type SARS-CoV challenge
irus replication and/or histopathological changes in immunized
nimals compared to mock-immunized controls. Due to individ-
al variation in responses of outbred animals, small groups of
onkeys (N = 4 or 5) are not large enough to evaluate statisti-
al outcomes in these studies. Therefore, special considerations
hould be given before conducting vaccine efficacy studies in
HPs. Challenge studies should be conducted in large numbers
N = 10–12 per group), and consideration should also be given
o the history of the animals used, utilizing the highest quality
f monkeys (avoiding those that have had free-range periods in
ife or those that are known to be infected with co-pathogens)
vailable (Roberts et al., 2006b). In vaccine efficacy studies,
mmunological responses should also be evaluated. Due to the
ack of available immunological reagents (including micro-array
ssays) for other NHP species, rhesus and cynomolgus macaques
re likely to be the most informative of the non-human primate
odels for continued SARS research. Despite the limitations of
HP models, evaluation of vaccine candidates in NHPs may be
ecessary to proceed to clinical studies. The cost for large studies
hat will provide the needed sample size and the other spe-
ial considerations mentioned will limit these vaccine efficacy
tudies to the most promising candidates.
.6. Summary of animal models
Although additional reports exist on other animal models
uch as farmed masked palm civets, guinea pigs, and voles
Chepurnov et al., 2004; Gao et al., 2005; Wu et al., 2005), there
re insufficient data available on these models to recommend
heir use in the evaluation of SARS-CoV vaccines and antiviral
rugs. Use of these models in such evaluations would neces-
itate a thorough characterization of the model, including viral
e
s
i
teplication data and histopathological analysis of SARS-CoV-
nd mock-infected animals. Different species may prove useful
or studying different aspects of SARS-CoV, and the study of
athogenesis may best be addressed in several species for which
ools are available for immunological analysis, whereas vaccines
nd antivirals may be studied in models that allow large enough
umbers for statistical evaluation.
The best animal model would be one that mimics human dis-
ase including features such as comparable levels of mortality to
hat seen in humans (∼10%) and increased susceptibility in older
nimals. It would likely be possible to develop such a model by
ncreasing virulence of SARS-CoVs for various species, as has
een done for influenza A, influenza B and Ebola viruses. Such
fforts are underway in mice and NHPs.
. Vaccines and immunotherapy for SARS
Although all the correlates of protection from SARS asso-
iated disease have not been identified in human infections,
eutralizing antibodies directed at SARS-CoV spike (S) pro-
ein are present in convalescent human serum (J.S. Zhang et
l., 2005) and have been detected in experimentally infected
nimals (Fouchier et al., 2003; Martina et al., 2003; McAuliffe
t al., 2004; Qin et al., 2005; Roberts et al., 2005a,b; Rowe et
l., 2004; Subbarao et al., 2004; Weingartl et al., 2004b; Wu
t al., 2005). In animal studies, neutralizing antibody provides
rotection from re-infection with SARS-CoV (Subbarao et al.,
004).
.1. Immunoprophylaxis and therapy
Prophylactically administered monoclonal antibodies spe-
ific to the SARS spike protein and passive transfer of
ARS-CoV hyper-immune sera to naive mice (Greenough et
l., 2005a; Subbarao et al., 2004; Sui et al., 2004; Traggiai
t al., 2004; X. Wang et al., 2005), hamsters (Roberts et al.,
006a) and ferrets (ter Meulen et al., 2004) prevent or reduce
ARS-CoV replication and associated disease following chal-
enge. Monoclonal antibodies specific to the SARS spike protein
dministered therapeutically (i.e. after the onset of infection)
revent further increase in viral burden and reduce associ-
ted disease (e.g. consolidation) in hamsters (Roberts et al.,
006a). Sera from mice immunized with recombinant spike pro-
ein, inactivated whole SARS-CoV, live-viral vectored vaccines
xpressing the spike protein (VSV-S or MVA-S) or DNA vac-
ines (expressing SARS-S and -M proteins) have been shown to
ontain neutralizing antibodies to SARS-CoV (Tables 3 and 4).
assive transfer of these immune sera to naive mice prevents
nfection with SARS-CoV (Bisht et al., 2004; Kapadia et al.,
005; Stadler et al., 2005; Yang et al., 2004). Although cell-
ediated immunity may have a protective role in viral clearance
r resolution of disease in the human population, antibody alone
as been shown to have both prophylactic and therapeutic ben-
fits in animal models. The data from several studies strongly
uggests that an effective SARS-CoV vaccine will be one that
nduces high and sustained levels of neutralizing antibodies and
hat administration of neutralizing MAbs specific to the SARS-
Table 2
Pulmonary replication of SARS-CoV in various animal models
Model (species) Input virus (dose) Viral titer (per gram)
achieved in lung
Peak virus titer
(day p.i.)
Reference(s)
Mouse (BALB/c) Urbani (105 TCID50) 107 TCID50 2 Roberts et al. (2005a),
Subbarao et al. (2004)
Mouse (129SvEv) Tor2 (107 TCID50) 106 TCID50 3 Hogan et al. (2004)
Urbani (105 TCID50) 106 TCID50 3 Authors’ unpublished data
Mouse (C57BL6) Urbani (104 TCID50) 107 TCID50 3 Glass et al. (2004)
Hamster (golden Syrian) Urbani 107 TCID50 2 Roberts et al. (2005b) and
authors’ unpublished data
HKU-39849 107 TCID50
Frankfurt 1 108 TCID50
icGD03 (103 TCID50) 104 TCID50
Ferret HKU-39849 (103–106 TCID50) 106 TCID50a 4 and 7 Martina et al. (2003), ter
Meulen et al. (2004)
NHP (cynomolgus) HKU-39849 (106 TCID50) 105.5 TCID50a,b 6 Kuiken et al. (2003)c
NHP (AGM) Urbani (106 TCID50) 107.2 TCID50a,d 2 and 4 McAuliffe et al. (2004)
NHP (rhesus) PUMC01 (105 TCID50) NRa,e 2, 5, and 7 Qin et al. (2005)
NHP (marmoset) Urbani (106 TCID50) NDf 2 and 4 Greenough et al. (2005b)
a Time corresponding to peak virus titer has not been determined; titers, if given, are for indicated day in bold-type, other days sampled are also given.
b Two of four macaques had undetectable levels of virus by viral titration assays; one had a titer of 105 TCID50 and one a titer of 106 TCID50/ml.
c Additional studies: Fouchier et al. (2003) reported virus in lung tissue by tissue culture (actual titer not reported) in one of two infected macaques, euthanized at
day 6 p.i.; McAuliffe et al. (2004) reported peak virus titers in tracheal lavage samples at 101.1 TCID50/g on day 2 p.i. in one of four macaques; Lawler et al. (2006)
reported detection of virus genome by RT/PCR in pharyngeal swabs intermittently at days 2–10 p.i. in eight of eight macaques tested.
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ad Peak titers were detected in right lobes of the lung and were much higher th
e NR: not reported; five of eight macaques had virus isolated from combined
f ND: none detected; virus was not isolated but viral genome was detected in
oV spike protein may be a useful strategy in post-exposure
reatment and prophylaxis in at risk populations.
.2. Recombinant protein and inactivated whole-virus
accines
The safety of vaccines should always be of paramount
onsideration and must always be empirically determined.
ecombinant protein vaccines are well accepted as being among
he safest vaccines although they are not always cost-effective.
ecombinant protein vaccines are excellent at eliciting ster-
able 3
eutralizing titers achieved following vaccination with
accine
dmin-
s-
ered
Reciprocal neutralizing titer (log2)
Pre-bleed and
Post-dose 1
Post-dose 2 Post-dose 3
ecombinant protein vaccine (Bisht et al., 2005)
Spikea + adjuvantb <3 8.3 10.0
L1Rc + adjuvantb <3 <3 <3
nactivated, whole-virus vaccine (Stadler et al., 2005)
BPL-SARSd + saline <3 <3 6.0
BPL-SARSd + adjuvante <3 6.5 9.3
BPL-Flud + adjuvante <3 <3 <3
a 10g/dose, s.c.
b Adjuvant = QS21 (saponin).
c L1R = vaccinia virus L1R protein.
d 5g total protein/dose, s.c.
e Adjuvant = MF59 (oil-in-water emulsion).
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crs from tracheal lavage samples collected on the same day.
and throat swabs, but actual titers are not reported.
homogenates by RT/PCR at the indicated times.
lizing immunity that can last up to several years depending
pon the immunogenicity of the protein. These vaccines do not
arry the risks of incomplete inactivation, genetic recombina-
ion with circulating viruses, or reversion to virulent phenotypes.
ecombinant proteins are often also very stable. Furthermore,
djuvants such as aluminum salts (Al(OH)3 and Al2(SO4)3 or
lum) or a squalene emulsion (MF59) (licensed for use in the
S and Europe, respectively) may be added to the formulation
f protein-based vaccines to increase immunogenicity.
The SARS-CoV spike (S) protein has been identified as the
ajor target of neutralizing antibodies (Buchholz et al., 2004;
ang et al., 2004; Sui et al., 2005; S. Wang et al., 2005; Z.Y.
ang et al., 2005; H. Zhang et al., 2004; Y. Zhang et al., 2004;
hao et al., 2004; Zhou et al., 2004). One study demonstrated
eutralizing antibodies specific for the membrane (M) protein
Pang et al., 2004). The role of antibodies specific to the SARS-S
rotein in conferring protection has also been well established
Greenough et al., 2005a; Roberts et al., 2006a; Subbarao et
l., 2004; Sui et al., 2005; ter Meulen et al., 2004; Traggiai et
l., 2004; X. Wang et al., 2005). As such, vaccines containing
ecombinant SARS spike proteins or neutralizing epitopes of the
pike protein should be fairly attractive. In fact, spike protein
nd trimers of spike proteins have been expressed from bac-
lovirus or semliki-virus-defective particle expression systems,
espectively, and were evaluated for their safety, immunogenic-
ty and efficacy in murine and hamster models (Bisht et al., 2005;
am et al., 2007). These proteins have demonstrated excellent
mmunogenicity (Tables 3 and 4) and efficacy in protection from
hallenge in animal models.
Table 4
Summary of SARS-CoV vaccine candidates that have demonstrated immunogenicity or efficacy
Animal model Immunogena Vaccine type Evaluation Challenge virus
used in efficacy
studies
References
Mouse Spike Recombinant protein
(baculovirus)
Efficacy Urbani Bisht et al. (2005)
±QS21
±MPL/TDMb
BPL(BJ01) Inactivated WVc Neutralizing Abs ND Tang et al. (2004)
±Al(OH)3
BPL-(FRA) Inactivated WVc Efficacy Urbani Stadler et al. (2005)
±MF59
BPL-(Tor2) Inactivated WVc Efficacy Tor2 See et al. (2006)
Formaldehyde (GZ50) Inactivated WV Neutralizing Abs ND Qu et al. (2005)
±alumd
±CpG
±CTBe
Formaldehyde (F69) Inactivated WVc Neutralizing Abs ND Xiong et al. (2004), C.H.
Zhang et al. (2005)
±Freund’s
±Al(OH)3
±CpG
UV (HKU-39849) Inactivated WVc Neutralizing Abs ND Takasuka et al. (2004)
±alumd
Formaldehyde + UV (Utah) Inactivated WVc Efficacy Utah Spruth et al. (2006)
±Al(OH)3
DNA-Spike DNA Efficacy Urbani Yang et al. (2004)
DNA-spike Combination Neutralizing Abs ND Woo et al. (2005)
±S peptide
DNA-Spike Combination Neutralizing Abs ND Zakhartchouk et al. (2005)
BPL(Tor2) + alumd
VSV-S Live-vectored Efficacy Urbani Kapadia et al. (2005)
MVA-S Efficacy Neutralizing Abs Urbani Bisht et al. (2004)
MVA-S Neutralizing Abs Efficacy ND Chen et al. (2005)
RV-S ND Faber et al. (2005)
AdS/N (Tor2) Tor2 See et al. (2006)
Hamster Spike-(HKU-39849) ± Al(OH)3 Recombinant protein Efficacy Urbani Kam et al. (2007)
BHPIV3-S Live-vectored Efficacy Urbani Buchholz et al. (2004)
Rabbit DNA-spike DNA Neutralizing Abs ND S. Wang et al. (2005)
Ferret rMVA-S (Tor2) Live-vectored Efficacy Tor2 Weingartl et al. (2004a)
NHPf
Cyno. BPL(BJ01) ± Al(OH)3 Inactivated WVc Efficacy BJ01 Qin et al. (2006)
Rhesus BPL(BJ01) ± alumd Inactivated WVc Efficacy GD01 Qin et al. (2006)
Rhesus Formaldehyde (ZJ01) Inactivated WVc Efficacy NS1 Zhou et al. (2005)
Rhesus MVA-S Live-vectored Efficacy PUMC01 Chen et al. (2005)
Rhesus AdS/N/M Live-vectored Neutralizing Abs ND Gao et al. (2003)
AGM BHPIV3-S Live-vectored Efficacy Urbani Bukreyev et al. (2004)
a The SARS-CoV strain that was used as the immunogen is designated in parentheses. If strain is not designated it is the Urbani strain. Urbani (AY278741); Tor2
(AY274119); FRA (AY310120); Utah (AY714217); HKU-39849 (AY278491); BJ01 (AY278488); NS1 (AY508724); ZJ01 (AY297028); GD01 (AY278489); GZ50
(AY304495).
b Sigma–Aldrich #M6536: 0.5 mg monophosphoryl lipid A (detoxified endotoxin) from S. minnesota (MPL) and 0.5 mg synthetic trehalose dicorynomycolate
(TDM) in 2% oil (squalene)–Tween 80–water.
c WV: whole-virus.
d alum: Al2(SO4)3.
e CTB: cholera toxin B subunit.
laris)
(
i
p
tf NHP: non-human primate; Cyno.: cynomolgus macaque (Macaca fascicu
Cercopithecus aethiops or Chlorocebus sabaeus).Inactivated, whole-virus vaccines have also been shown to be
mmunogenic and efficacious (Tables 3 and 4). Like recombinant
rotein vaccines, these vaccines contain substantial amounts of
he spike protein, and they elicit neutralizing antibodies at lev-
e
(
v
t, Rhesus: rhesus macaque (Macaca mulatta), AGM: African green monkeyls similar to those elicited by recombinant protein vaccines
Table 3) that confer protection from subsequent challenge in
accinated animals. Like recombinant protein vaccines, inac-
ivated, whole-virus vaccines would likely have a relatively
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dtable formulation. Potential benefits of inactivated, whole-virus
accines over recombinant protein vaccines are that the con-
ormation of the spike protein may be maintained and that
ntibodies to other viral proteins may contribute to protective
mmunity. Major disadvantages of inactivated, whole-virus vac-
ines would be the need to work with whole infectious virus in
he preparation of the vaccine and the potential for incomplete
nactivation in the processing and manufacturing of the vaccine.
.3. Vectored vaccines
Although vaccines that elicit both humoral and cellular
mmunity may provide theoretical advantages, vaccines that
roduce a neutralizing antibody response may be sufficient for
rotection from SARS-CoV infection. Convalescent human sera
ad a mean plaque reduction neutralization titer of 1:61 with a
ormal distribution of titers around the mean (J.S. Zhang et al.,
005) but the titer of neutralizing antibodies necessary to achieve
rotection in a human population exposed to SARS-CoV is not
nown. A recombinant-, DNA-, or live-vectored vaccine, or a
ombination of these, have the advantage that laboratory workers
re not exposed to live SARS-CoV during vaccine production.
Although DNA vectors have potential to be safe, stable and
elatively inexpensive vaccines, they have not been proven to
e highly efficacious or immunogenic in humans. When DNA
accines expressing the SARS-S protein were evaluated in mice,
hey stimulated both humoral and cell-mediated immunity (Z.
ang et al., 2005; Yang et al., 2004) and were efficacious. Anti-
odies to the S gene were responsible for protection (Yang et al.,
004). SARS-CoV DNA vaccines have demonstrated greater
otential in prime-boost regimens in species in which robust
mmunity is not induced by a DNA vector alone (Table 4). How-
ver, such combinations may lessen the economic benefit of a
NA-vector approach and necessitate licensure of more than
ne vaccine for human use.
Several live viruses have been tested as vectors to express
ARS-CoV proteins, including BHPIV3, MVA, VSV and ade-
ovirus (Table 4). Not all vectors were equally immunogenic,
nd efficacy data were not available from all the studies. Nev-
rtheless, those vectors that elicited neutralizing antibodies and
rotective immunity were those that expressed the spike protein
f SARS-CoV. Vectors expressing other SARS-CoV proteins
ncluding M and N did not confer protection from challenge
ith SARS-CoV, and the addition of the M and N genes did
ot enhance the immunogenicity or efficacy or the vaccine
ncoding the spike protein alone (Buchholz et al., 2004). In
enescent mice, immunization with a vectored vaccine express-
ng the SARS-CoV N protein alone, or with co-administered
pike protein. Enhanced pathology was seen following chal-
enge (Deming et al., 2006). A summary of the vectored vaccines
ested, their immunogenicity and protective efficacy and the ani-
al models in which they were tested are listed in Table 4. Of
ll the live-vectored vaccines tested to date, only one construct
MVA-S) was variably immunogenic and variably efficacious.
n ferrets, vaccination with this vector did not confer protection
nd may have led to formation of hepatic lesions following chal-
enge with SARS-CoV. These findings contrast with other data
h
w
o
2eported using a MVA-S-vectored vaccine in mice and rhesus
acaques where they were significantly immunogenic and effi-
acious. It is possible that the immunogenicity of MVA-vectored
accines, like DNA vaccines varies in different species.
.4. Combination vaccines
Finally, combination vaccines may prove to be more immuno-
enic than DNA vaccines, inactivated vaccines, or vectored
accines alone. A thorough study of a combination of DNA
nd peptide vaccines demonstrated that such a regimen greatly
nhanced the neutralizing antibody response to the SARS-S pro-
ein (Woo et al., 2005). However, the complexity of developing
wo systems and requiring a prime/boost regimen are disad-
antages in comparison to a single immunization with a highly
mmunogenic vaccine. One may question whether a more com-
lex regimen is warranted if a single vaccine administered once
an produce sterilizing immunity.
. The potential for enhanced disease following use of
ARS vaccines
.1. Enhancement of disease in vivo with the type-1
oronavirus FIPV and other viruses
Enhanced disease and mortality have been observed in kittens
mmunized against feline infectious peritonitis virus (FIPV), a
ype-I coronavirus, when they were subsequently exposed to
IPV (Vennema et al., 1990; Weiss and Scott, 1981). Enhanced
isease associated with FIPV is not well understood but appar-
ntly is mediated by sub-neutralizing antibodies that facilitate
iral entry into macrophages via an Fc-receptor-mediated mech-
nism (Corapi et al., 1992, 1995; Hohdatsu et al., 1991, 1993;
lsen et al., 1992, 1993). In the absence of serotype-specific
rotective antibodies or in the presence of low levels or sub-
eutralizing levels of virus specific antibody, other human
iruses including respiratory syncytial virus (RSV) and dengue
irus demonstrate enhanced disease upon re-infection (Connors
t al., 1992a,b; Halstead, 2003; Kakuk et al., 1993; Murphy
t al., 1990; Sullivan, 2001). Disease enhancement in cases
f RSV occurs in the absence of protective titers of antibod-
es and is likely mediated by cellular immune responses that
ead to immunopathology. Antibody dependent entry observed
n dengue virus infections is similar to that which occurs in
IPV infection. In dengue virus infections, antibody enhanced
ntry occurs after previously infected individuals are re-infected
ith a second serotype of dengue virus. The antibodies to
he first serotype of dengue virus are not protective against
he second serotype, and virus entry into susceptible cells is
acilitated through Fc-receptor-mediated mechanisms by these
on-protective antibodies.
Although SARS-CoV antigen and nucleic acid have been
etected in pulmonary macrophages in lungs from infected
umans and experimentally infected animals, it is unclear
hether this is due to phagocytosis of virions or to antibody-
r receptor-mediated viral entry (Li et al., 2003; Yilla et al.,
005). Macrophages infected ex vivo do not support repli-
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Research Program of the NIH, NIAID. We acknowledge Dr.ation of SARS-CoV, a type-II coronavirus. However, as
iscussed below, there are some in vitro data to suggest that
nhanced entry of SARS-CoV into susceptible cells may occur
n the presence of non-neutralizing or sub-neutralizing levels of
ntibodies.
.2. Enhancement of viral entry in vitro
Pseudo-typed lentiviruses, expressing the spike protein from
SARS-CoV isolated from civet cats, have demonstrated
nhanced entry into a human renal adenocarcinoma cell line
86-O when incubated with antibodies to human SARS-CoV
solates (Z.Y. Yang et al., 2005). Enhancement was not observed
ith pseudo-typed viruses expressing the spike protein of a
uman SARS-CoV isolate. Enhancement has only been demon-
trated at the level of virus entry and not in virus replication,
nd it is yet to be determined if enhanced replication occurs
n the presence of sub-neutralizing levels of antibodies. Fur-
hermore, these in vitro findings have not been linked to any
nown component of human disease or infection in vivo in
nimal models; this phenomenon has only been reported with
seudo-typed viruses and has not been observed with human
solates of SARS-CoV; and these observations in 786-O cells
ere not reproducible according to He et al. (2006). Further
n vitro experiments examining productive or enhanced SARS-
oV (HK-39) replication in differentiated human macrophages
n the presence or absence of SARS-specific antibodies demon-
trated that SARS-CoV was able to enter these cells and that
ntry was not enhanced by antibody to SARS-CoV. Viable virus
as not recovered from these macrophage cultures two days
fter viral entry, and qRT-PCR analysis showed little to no
iral replication in these cells (ter Meulen et al., 2006). Ex vivo
xperiments examining SARS-CoV (Urbani and mouse-adapted
train MA15, Roberts et al., 2007) replication in primary murine
BALB/c, BL/6 and 129S6 strains) macrophages, isolated
rom the lungs, spleen and peritoneum, failed to demon-
trate productive infection as well (Roberts et al., unpublished
ata).
.3. Enhancement of disease in vivo with SARS-CoV
Several experiments have evaluated SARS-CoV infection
n various animal models in the presence of neutralizing and
ub-neutralizing levels of SARS-antisera or MAbs specific to
ARS-CoV S protein. Evidence of disease enhancement has
ot been seen in any of the studies where appreciable levels
f neutralizing antibodies were achieved following vaccination
See references in Table 4). Furthermore, enhanced disease has
ot been reported in respiratory tissues or in GI tissues, which
re the primary sites of viral replication in SARS-CoV infec-
ion. In a single set of experiments (Weingartl et al., 2004a),
errets were immunized with MVA-SARS-S via interperitoneal
nd subcutaneous routes with 108 pfu of vaccine per ferret at
ay 0, boosted with the same regimen at day 14, and chal-
enged intranasally with 106 pfu/ferret of SARS-CoV (Tor2) at
ay 28. MVA-SARS-S vaccinated ferrets demonstrated low lev-
ls of neutralizing antibodies to SARS-CoV 1 week after the
M
f
C
mooster immunization (i.e. day 21; titer 1:40 or less). Strangely,
eutralizing antibodies in this group were not detectable at day
8 (<1:20), prior to challenge and no significant difference was
bserved in the level of virus detected in pharyngeal swabs from
nimals vaccinated with MVA-SARS-S and control animals
ollowing challenge with SARS-CoV. Foci of hepatic necro-
is were observed in MVA-SARS-S-vaccinated animals and to
lesser extent, in animals immunized with the MVA vector
lone or PBS. It is unclear why the MVA-SARS-S vaccine was
o poorly immunogenic (indicated by low level and transient
etection of neutralizing antibodies) in ferrets since a similar
accine was immunogenic and efficacious in mice and NHPs. It
s also unclear why a memory antibody response was observed
n MVA-SARS-S-immunized animals but was unable to neutral-
ze virus or clear virus from these ferrets any faster than virus
as cleared from mock-immunized ferrets. The possibility of
o-pathogens as a cause for hepatitis was not examined, and it
s possible that co-pathogens might have played a role in the
bservations reported in these ferrets. It is also possible that
he observed phenomenon may be limited to a specific vector
MVA) or animal model (ferrets). Finally, although elevated lev-
ls of liver enzymes following SARS-CoV infection have been
eported in human cases of SARS, hepatitis was rarely if ever
eported in SARS patients (Z. Yang et al., 2005). Therefore, it
s difficult to interpret the findings of hepatitis in ferrets and to
etermine if these findings have any relevance to the possibility
f disease enhancement in SARS-vaccinated animals. Although
nconfirmed, it may be possible that hepatic lesions observed in
his study occur through cell-mediated mechanisms similar to
hat observed in the lungs in RSV infection following the use of
formalin inactivated vaccine. The finding of hepatitis follow-
ng use of this MVA-vectored vaccine in ferrets merits further
valuation.
. Summary
Although all of the correlates of immunity are not known
or human cases of SARS or for current SARS animal models,
uch is now known about generating protection against SARS-
oV infection. Vaccines and monoclonal antibodies specific to
ARS-CoV spike protein are highly efficacious in prophylaxis.
lthough concerns regarding potential enhancement of disease
n previously vaccinated animals are being addressed experi-
entally, the body of literature supporting complete and partial
rotection in several animal models following a variety of vac-
ine strategies suggests that a successful SARS vaccine can be
ade.
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